tm logo
BYVEZMA
WITHDRAWN BY OWNER

on 15 Jun 2023

Last Applicant/ Owned by

REGENERON PHARMACEUTICALS INC.

777 Old Saw Mill River RdTarrytown, NY 10591

US

Serial Number

2245197 filed on 13th Mar 2023

Correspondent Address

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

BYVEZMA

Trademark usage description

pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutica Read More

Classification Information


Class [005]
Pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections.; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of immunological disorders; pharmaceuticals for treating respiratory diseases


Classification kind code

12

Mark Details


Serial Number

2245197

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 5
on 15th Jun 2023
Withdrawn by Owner
Submitted for opposition 30
on 13th Mar 2023
Filed
Submitted for opposition 1
on 13th Mar 2023
Created
Submitted for opposition 31
on 13th Mar 2023
Formalized